Method for predicting risk of cerebral infarction
The method predicts cerebral infarction risk by detecting the RNF213 p.R4810K polymorphism and gender information, addressing the lack of effective prediction methods and enabling early preventive measures.
Patent Information
- Application Number
- JP2022194528
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2022-12-05
- Publication Date
- 2024-11-27
- Estimated Expiration
- 2038-12-13
AI Technical Summary
Current methods fail to effectively predict the risk and timing of cerebral infarction, particularly in populations with genetic predispositions such as those carrying the RNF213 p.R4810K polymorphism, which is associated with moyamoya disease and atherosclerosis.
A method is developed to detect the presence of the RNF213 p.R4810K gene polymorphism in subjects, combined with gender information, to predict the risk and timing of cerebral infarction by classifying it into atherothrombotic, lacunar, and embolic types.
This method allows for early prediction of cerebral infarction, enabling preventive measures and reducing the risk of stroke onset by identifying high-risk individuals based on genetic markers.
Smart Images

Figure 0007590739000007 
Figure 0007590739000008 
Figure 0007590739000009
Abstract
Description
[Technical field]
[0001] The present invention relates to prediction of the risk of developing cerebral infarction and the timing of onset, and to the research field thereof, and in particular to a method for predicting the risk of developing cerebral infarction and a method for predicting the risk of developing cerebral infarction using gender information. [Background technology]
[0002] Non-patent document 1 discloses that the RNF213 gene polymorphism (c.14576G>A, p.R4859K, rs112735431), which is a susceptibility gene for moyamoya disease, is significantly associated not only with moyamoya disease, but also with unilateral moyamoya disease and intracranial major artery stenosis (intracranial stenosis) due to atherosclerosis, while also disclosing that the RNF213 gene polymorphism was not significantly associated with cervical carotid artery stenosis, cerebral aneurysm, or intracerebral hemorrhage.
[0003] In addition, the notation of the RNF213 gene polymorphism in Non-Patent Document 1 as (c.14576G>A, p.R4859K, rs112735431) is based on the nomenclature by the Tohoku University group. In this specification, the same RNF213 gene polymorphism is referred to as the p.R4810K polymorphism (c.14429G>A, rs112735431) or simply the p.R4810K polymorphism, based on the nomenclature by the Kyoto University group. Both are due to differences in the way amino acids are counted, and are the same polymorphism. [Prior art documents] [Non-patent literature]
[0004] [Non-Patent Document 1] "RNF213 and Moyamoya syndrome", Satoshi Miyawaki, Niche Neuro-Angiology Conference 2016, http: / / nnac.umin.jp / nnac / NNAC_2016_files / %E5%AE%AE%E8%84%87%E5%85%88%E7%94%9F.pdf Summary of the Invention [Problem to be solved by the invention]
[0005] An object of the present invention is to provide a method for predicting the likelihood of developing cerebral infarction. [Means for solving the problem]
[0006] Cerebral infarction is classified into three types: atherothrombotic brain infarction, lacunar infarction, and cerebral embolism.
[0007] The present inventors' study revealed that there is a significant correlation between the RNF213 p.R4810K gene polymorphism and atherothrombotic cerebral infarction. This provides a method for predicting the risk of developing cerebral infarction and the time of onset (or a method for auxiliary prediction) of the onset of cerebral infarction in a subject by detecting the presence or absence of the RNF213 gene polymorphism in a sample derived from the subject who has not yet developed cerebral infarction.
[0008] The present invention includes the following inventions. (1) a detection step of detecting the presence or absence of the RNF213 p.R4810K genetic polymorphism in a sample derived from a subject who has not yet experienced cerebral infarction; a determination step of determining whether or not the subject has a high probability of developing cerebral infarction based on the presence or absence of the RNF213 p.R4810K genetic polymorphism in the detection step and on the gender information of the subject; A method for predicting the risk of developing cerebral infarction in a subject who has not yet developed cerebral infarction, comprising:
[0009] (2) The method according to (1) above, wherein, when the RNF213 p.R4810K genetic polymorphism is detected in the detection step, the subject is determined to be at higher risk of developing cerebral infarction in the determination step, as compared to a person who does not have the RNF213 p.R4810K genetic polymorphism.
[0010] (3) The method according to (1) or (2) above, wherein, when the RNF213 p.R4810K genetic polymorphism is detected in the detection step, the determination step determines that the subject is at a higher risk of developing cerebral infarction if the subject is female compared to if the subject is male.
[0011] (4) A genetic marker consisting of the RNF213 p.R4810K gene polymorphism for predicting the risk of developing cerebral infarction using gender information.
[0012] (5) A biomarker consisting of a polypeptide encoded by the RNF213 p.R4810K gene for predicting the risk of developing cerebral infarction using gender information. Effect of the Invention
[0013] The findings of the present invention make it possible to predict the onset of cerebral infarction and to take preventive and countermeasure measures at an early stage for subjects who have not yet experienced cerebral infarction. [Brief description of the drawings]
[0014] [Figure 1] In Example 1, a flow chart of the patient selection procedure is shown. [Diagram 2] FIG. 1 shows a box plot of the mean age at onset of stroke depending on the presence or absence of the RNF213 p.R4810K polymorphism in Example 1. [Diagram 3] FIG. 2 is a bar graph of gender-specific differences in carrier frequencies of the RNF213 p.R4810K polymorphism among stroke subtypes in Example 1. The bars on the left are men and the bars on the right are women. [Figure 4] In Example 2, a flow chart of the patient selection procedure is shown. [Diagram 5] FIG. 1 is a pie chart showing the prevalence of the RNF213 p.R4810K polymorphism. The left pie chart is for all 70 patients in Example 2, and the right pie chart is for the general population as previously reported. [Figure 6]FIG. 1 shows pie charts illustrating the difference in prevalence of the RNF213 p.R4810K polymorphism between the sexes in Example 2, with the left pie chart for men (N=44) and the right pie chart for women (N-26). [Figure 7] FIG. 13 is a pie chart showing the difference in the prevalence of the RNF213 p.R4810K polymorphism depending on the presence or absence of M1 / A1 stenosis in Example 2. The left pie chart is for the case with stenosis (N=48), and the right pie chart is for the case without stenosis (N=22). [Figure 8] 1 shows image data of a representative case (Case 6 in Table 6) having the RNF213 p.R4810K polymorphism in Example 2. (A) is an MRI diffusion-weighted image, (B) is an MRA image, and (C) is an MRA image taken 5 years after the onset of cerebral infarction. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] RNF213 (Ring finger protein 213) (GenBank accession number NM_001256071.1) was recently identified as a disease susceptibility gene for moyamoya disease and is located in the human chromosome region 17q25.3.
[0016] The RNF213 p.R4810K gene polymorphism is a single nucleotide polymorphism (SNP) of 73097 G>A in the nucleotide sequence shown in SEQ ID NO: 2. As described in the above-mentioned prior art, RNF213 p.R4810K is known as a moyamoya disease susceptibility polymorphism.
[0017] The present inventors' research has revealed that the RNF213 p.R4810K polymorphism increases the risk of ischemic stroke (i.e., cerebral infarction) due to aortic atherosclerosis. In this specification, ischemic stroke is synonymous with cerebral infarction.
[0018] Ischemic stroke is one of the causes of premature death in recent years and is a leading cause of disability and premature death, especially in Asia, but the genetic correlation between ischemic stroke and ischemic stroke remains unknown. Moyamoya disease, a cerebrovascular disease mainly identified in East Asia, is associated with a susceptibility gene, RING finger protein 213 (RNF213), whose dysregulation impairs cerebral perfusion in mouse brains. We therefore hypothesized that RNF213 plays a more general role in ischemic stroke and investigated the association of the p.R4810K polymorphism in the RNF213 gene, the most common risk for moyamoya disease, with ischemic stroke and its subtypes.
[0019] The RNF213 p.R4810K genetic polymorphism is a single nucleotide polymorphism (SNP) of 73097 G>A in the nucleotide sequence represented by SEQ ID NO: 2, and can be a genetic marker for predicting or assisting in the prediction of the risk of developing cerebral infarction.
[0020] Sequence number 2 is a partial nucleotide sequence of human chromosome 17 DNA containing the mysterin gene and genes in its surrounding region [FLJ3520, NPTX1, CARD14, and Raptor (KIAA1303)], and corresponds to nucleotides 43560001 to 43795000 of Contig #NT010783.15 registered in NCBI.
[0021] In addition to the SNP at position 73097, which is either G or A (abbreviated as 73097 G>A herein), the nucleotide sequence represented by SEQ ID NO:2 contains SNP at position 4766, which is T or C (4766 T>C), SNP at position 120764, which is G or A (120764 G>A), A SNP at position 152917 that is either G or A (152917 G>A), and There can also be a SNP at position 232102 which is either G or A (232102 G>A).
[0022] In this specification, the position of an SNP is described based on the position of the nucleotide in the nucleotide sequence shown in SEQ ID NO: 2. For example, "SNP at position 73097" means an SNP at the nucleotide at position 73097 in the nucleotide sequence shown in SEQ ID NO: 2. When describing "73097 G>A", the major allele base (G in this case) is described before the ">" symbol, and the minor allele base (A in this case) is described after it.
[0023] Furthermore, in this specification, nucleotide sequences are described as DNA sequences unless otherwise specified, but when the polynucleotide is RNA, thymine (T) should be read as uracil (U) as appropriate.
[0024] In the present invention, a polynucleotide may contain any additional sequence in addition to a continuous partial sequence of the nucleotide sequence shown in SEQ ID NO: 2 or a complementary sequence thereof.
[0025] In the present invention, the polynucleotides are preferably isolated or purified.
[0026] In the detection step of the above-mentioned method of the present invention, the SNP 73097 G>A is detected in a biological sample collected from a subject.
[0027] The race of the human is not particularly limited, but is preferably East Asian (East Asian / Mongoloid).
[0028] Here, a race is a distinct subgroup of the Homo sapiens species. Races have distinctive, distinguishable combinations of genes and are identified by the characteristics (both mental and physical) that are produced by those combinations. Members of the same race share common genetic ancestry and, as a result, share similar combinations of genes, and therefore share distinct genetic characteristics.
[0029] For example, the genetic relationships of the world's major human populations have been examined based on information from 23 types of genes, and they have been classified into five types: African (Negroid), Caucasian (Caucasian), Oceanian (Australoid), East Asian (Mongoloid), and Native American.
[0030] By East Asian is meant a person of any of the following origins: Japanese, Korean, Chinese, Taiwanese and Mongolian. An East Asian is preferably Japanese, Korean or Chinese.
[0031] Those skilled in the art can readily determine an individual's race based on their physical characteristics, country of origin, information about ancestral origins, and the like.
[0032] The biological sample used in the above method can be any tissue, cell, body fluid, etc. from which genomic DNA can be extracted. From the standpoint of ease of acquisition and minimal invasiveness, however, hair, nails, skin, mucous membranes, blood, plasma, serum, saliva, etc. are preferably used.
[0033] Methods for detecting SNPs are well known in the art. For example, RFLP (restriction fragment length polymorphism) method, PCR-SSCP (single-stranded DNA conformation polymorphism analysis) method, ASO (allele specific oligonucleotide) hybridization method, sequencing method, ARMS (amplification refracting mutation system) method, denaturing gradient gel electrophoresis method, RNAseA cleavage method, DOL (dye-labeled oligonucleotide ligation) method, TaqMan PCR method, primer extension method, Invader method, etc. can be used.
[0034] In addition, the polypeptide encoded by the RNF213 p.R4810K gene is a polypeptide containing the amino acid sequence represented by SEQ ID NO:1 (in which arginine at position 4810 in the amino acid sequence represented by SEQ ID NO:1 is replaced with lysine), and can be a biomarker for predicting the risk of developing cerebral infarction.
[0035] In other words, as mentioned above, the RNF213 p.R4810K SNP mutation involves an amino acid substitution at position 4810 of human mysterin (arginine to lysine), so by isolating mysterin polypeptide from a subject and identifying the amino acid at position 4810, it is possible to predict or assist in the prediction of the risk of developing cerebral infarction. EXAMPLES
[0036] The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples.
[0037] [Example 1: Association between atherothrombotic cerebral infarction and RNF213p.R4810K polymorphism] Stroke mortality rates have declined over the past few decades 1) However, stroke is the second leading cause of premature death and the leading cause of disability worldwide. 2) In Southeast and East Asia, which accounts for 31% of the world's population, stroke is the leading cause of premature death and stroke incidence and prevalence are steadily increasing. 1,2) Epidemiological studies suggest substantial geographic and racial variations in stroke subtypes. 3,4) Myocardial embolism is a common etiological subtype of ischemic stroke in the Western world. 5) On the other hand, large-artery atherosclerosis due to intracranial arterial stenosis is the major etiology in most Asian countries. 6)Environmental risk factors and differences in genetic background are believed to be the main reasons for the high prevalence of large artery atherosclerosis in Asia. Recently, a large-scale multiancestry genome-wide association meta-analysis identified 32 loci associated with stroke and stroke subtypes. 7) Approximately 8 million single nucleotide polymorphisms (SNPs) were examined in this study. However, the analysis excluded region-specific rare alleles with minor-allele frequencies (MAFs) below 0.01 and the Asian-specific genetic determinants of ischemic stroke remain unknown.
[0038] The RING finger protein 213 gene (RNF213) on 17q25.3 has been identified as a susceptibility gene for moyamoya disease. 8,9) The RNF213 p.R4810K polymorphism (c.14429G>A, rs112735431) was detected in more than 80% of patients with moyamoya disease, whereas the allele carrier frequency in East Asian healthy subjects was approximately 2%. 8,9) RNF213 is a 591 kDa protein that functions as both an AAA+ ATPase and an E3 ligase. 12) , which codes for , and is associated with the development of intracranial occlusive lesions and compensatory adaptation to reduced cerebral blood flow. 13,14) Recently, two separate center studies reported a high frequency (20–25%) of the RNF213 p.R4810K polymorphism in East Asian non-moyamoya patients with intracranial internal carotid artery stenosis or proximal middle cerebral artery stenosis. 10,15) Therefore, we hypothesized that this genetic variant may be associated with overall ischemic stroke in Asia. Here, we analyzed acute ischemic stroke patients who participated in a study at the National Cerebral and Cardiovascular Center (NCVC) and investigated the association of the RNF213 p.R4810K polymorphism with ischemic stroke and its subtypes.
[0039] (method) (Study design and participants) The case-control study used the National Center for Cardiovascular and Venous Diseases (NCVC) hospital-based single population (NCVC Biobank) that contains extensive clinical and radiological data of all patients. Written informed consent was obtained from all study participants, and the study was approved by the ethics committee of the National Center for Cardiovascular and Venous Diseases (NCVC).
[0040] (the study) Participants for this study were recruited at the National Cerebral and Cardiovascular Center (NCVC), a 600-bed tertiary center specializing in stroke and cardiovascular disease in the Osaka, Kansai region. A total of 383 Japanese patients with noncardiogenic cerebral embolism (large-artery atherosclerosis, small-vessel occlusion, etc.) who were hospitalized between June 2012 and May 2017 and signed a comprehensive informed consent form at NCVC were included in this study. Patients who were diagnosed with cardiogenic cerebral embolism, cardioembolic stroke, or definite / probable moyamoya disease based on the criteria of the Moyamoya Disease Research Committee of the Ministry of Health, Labor, and Welfare of Japan were excluded. 17) A flow diagram of the patient selection procedure is detailed in Figure 1.
[0041] Demographic data, atherosclerotic risk factors, radiological findings, and medical history were obtained from a prospectively-collected database of stroke patients. Stroke subtypes were classified according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. 18) Cerebrovascular lesions were identified by magnetic resonance imaging (MRI) and MR angiography or CT and CT angiography. directionAnterior circulation stenosis is a research criterion of Warfarin-Aspirin Symptomatic Intracranial Disease (WASID). 19) According to the 2010 American Heart Association (AHA), a reduction in diameter of >50% was defined as a reduction in diameter of the intracranial internal carotid artery, middle cerebral artery, or anterior cerebral artery. direction Posterior circulatory stenosis was defined according to the above criteria in the intracranial, retrospinal, or posterior cerebral arteries.
[0042] Control subjects were recruited in the Kansai region of Japan between 2007 and 2015. Among the 1,027 potential controls, 16 subjects with a history of cerebral infarction or moyamoya disease were excluded. Finally, 1,011 control subjects were selected. Venous blood samples were collected upon admission and stored at −80°C until analysis. 8) Genotyping of p.R4810K was performed using TaqMan SNP Assays (Applied Biosystems, Foster City, CA) and the 7300 / 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA) as described previously.
[0043] SNP genotyping was performed at the RIKEN Center for Integrative Medical Sciences using a combined analysis of Illumina HumanOmniExpress BeadChip and HumanExome BeadChip, or Illumina Human OmniExpressExome BeadChip analysis. Haplotype phasing and genotype imputation were performed using filtered samples with genotype data that passed quality control criteria, including success rate and Hardy-Weinberg equilibrium test. Genome-wide association studies (GWAS) were performed using the imputed allele dosages and fitted to a logistic regression model with an additive genetic model. We incorporated 10 principal components, age, and sex as covariates. Details have been described previously. 7) .
[0044] (Statistical analysis) Continuous variables were expressed as mean ± SD and compared using Student's t-test. Categorical variables were expressed as numbers and percentages and compared using chi-square test and two-tailed Fisher's exact test as appropriate. We tested the association between RNF213 polymorphism and risk of ischemic stroke assuming a dominant model in this study due to insufficient number of homozygotes. We also examined the association under a log-additive model for meta-analysis to compare with replication studies using imputation methods. Multiple logistic regression models were used to calculate odds ratios (OR ratios) and 95% confidence intervals (95% CI) for each stroke subtype after simultaneously controlling for potential confounding factors. Variables considered in the model were age (continuous), sex, hypertension, dyslipidemia, diabetes, and smoking. All analyses were performed using JMP Pro 12.2 software (SAS Institute Inc., Cary, NC).
[0045] Probability values were two-sided and p<0.05 was considered significant. Meta-analysis was performed with p<5x10 -8 The analysis was performed with Review Manager (RevMan) 5.3 software (The Nordic Cochrane Center, Copenhagen, Denmark) using an inverse variance fixed effects model in which all phenotypes were considered significant genome-wide.
[0046] (result) This study specifically enrolled patients with noncardioembolic stroke. Of the 1,775 noncardioembolic stroke patients who met the above inclusive criteria, 383 (21.6%) agreed to participate in the NCVC Biobank and were analyzed in this study. The characteristics of both NCVC Biobank participants and nonparticipants are shown in Table 1. The baseline characteristics of the study participants are also shown in Table 1.
[0047] [Table 1]
[0048] The RNF213 p.R4810K polymorphism was found in 5.2% of noncardioembolic stroke patients and 2.1% of healthy controls (crude OR 2.60, 95% CI 1.39-4.85, p=0.0019). After adjusting for age, sex, and atherosclerotic risk factors, the association of the RNF213 p.R4810K polymorphism with noncardioembolic stroke remained significant (adjusted OR 3.90, 95% CI 1.62-9.24, p=0.0026). Compared to control subjects, large-artery atherosclerosis was significantly associated with the polymorphism (crude OR 5.19, 95% CI 2.53-10.64, p=2.6x10 -6 , adjusted OR 11.45, 95% CI 3.46-36.17, p=0.0001) (Table 2).
[0049] [Table 2]
[0050] In a comparison between stroke patients with and without the RNF213 p.R4810K polymorphism, the average age at onset of stroke was 11 years lower in the RNF213 polymorphism than in non-carriers (58.1 ± 15.5 years vs. 69.1 ± 13.2 years, p = 0.0003) (Figure 2). Figure 2 shows a box plot of the average age at onset of stroke by the presence or absence of the RNF213 p.R4810K polymorphism.
[0051] In stroke patients, RNF213 polymorphism carriers were more likely to be female (55.0% vs. 27.3%, p = 0.011) and had a higher incidence of intracranial pre-stroke than non-carriers. direction The study showed a higher frequency of circulatory stenosis (60.0% vs. 27.3%, p = 0.004) and aortic atherosclerosis (65.0% vs. 32.5%, p = 0.012). direction The occurrence of posterior circulation stenosis and traditional atherosclerotic risk factors, such as the incidence of hypertension, diabetes, dyslipidemia, and smoking, did not differ between polymorphism carriers and noncarriers. These results are summarized in Table 3.
[0052] [Table 3]
[0053] Further, details on the carrier frequency of the RNF213 p.R4810K polymorphism stratified by gender in each stroke subtype are shown in Table 4. Also, Figure 3 shows the gender-specific difference in the carrier frequency of the RNF213 p.R4810K polymorphism between stroke subtypes in a bar graph. The left bar is for men, and the right bar is for women.
[0054] [Table 4]
[0055] As shown in Table 4, in both men and women, the RNF213 p.R4810K polymorphism was significantly associated with all non-cardioembolic strokes and atherothrombotic, respectively. More preferably, there was a significant correlation between women with the RNF213 p.R4810K polymorphism and all non-cardioembolic strokes (adjusted OR 9.8, 95% CI 3.1-30.9, p<0.001), and between the RNF213 p.R4810K polymorphism and atherothrombotic (adjusted OR 58.0, 95% CI 10.3-327.3, p<0.001).
[0056] As described above, this study revealed that the average age of stroke onset was 11 years younger in carriers of the RNF213 p.R4810K polymorphism, and that the carrier frequency of the RNF213 p.R4810K polymorphism was very high in patients with acute non-cardioembolic stroke, especially in female patients with atherothrombotic brain infarction.
[0057] In conclusion, the RNF213 p.R4810K polymorphism is a genetic risk factor for non-cardioembolic stroke, and when combined with gender information, it may be a more favorable genetic risk factor for atherothrombotic brain infarction.
[0058] [Example 2: Association between early-onset stroke with intracranial arterial stenosis and RNF213p.R4810K polymorphism] RNF213 has been identified as a susceptibility gene for moyamoya disease, and the RNF213 p.R4810K polymorphism is present in more than 90% of Japanese patients with moyamoya disease. RNF213 is thought to play an important role in regulating endothelial function and angiogenesis, but the mechanism by which it causes specific vascular disorders such as moyamoya disease has not been fully elucidated. On the other hand, it has been recently reported that this gene polymorphism is present in 2-3% of healthy adults in Asia, including Japan, and that 20-25% of patients with intracranial arterial stenosis who have not been diagnosed with moyamoya disease also possess this gene polymorphism. It has been suggested that this gene polymorphism may also be a risk factor for cerebrovascular disorders other than moyamoya disease.
[0059] In this study, we investigated the prevalence of the RNF213 p.R4810K polymorphism in young cerebral infarction patients under 60 years of age, and aimed to clarify the association between this gene polymorphism and young cerebral infarction. In the term "young cerebral infarction" in this specification, "young" generally means up to the age of 60 (before the 60th birthday).
[0060] (Research design and subjects) This study was a single-center cross-sectional study of patients registered in the National Cerebral and Cardiovascular Center (NCVC) biobank. All 70 registered patients aged 20 years to 60 years with intracranial arterial stenosis who had noncardioembolic stroke or transient ischemic attacks (TIA) were included. Patients diagnosed with cardioembolic stroke and moyamoya disease were excluded. Written informed consent was obtained from all subjects, and the study was approved by the ethics committee of the National Cerebral and Cardiovascular Center (NCVC).
[0061] (Selection Criteria) The inclusion criteria for subjects were as follows: [1] Patients who agreed to participate in the National Cerebral and Cardiovascular Center (NCVC) biobank program. [2] Patients aged 20 years or older and under 60 years who have suffered an ischemic stroke or transient ischemic attack. [3] Patients with 50% or greater (diameter) stenosis or occlusion in at least one of the following intracranial arteries:
[0062] Intracranial internal carotid artery (ICA), Middle cerebral artery M1-2 segment, Anterior cerebral artery A1-2 segment, posterior cerebral artery (posterior circulation stenosis) P1-2 segment, Basilar artery.
[0063] (exclusion criteria) Patients with cardiogenic cerebral embolism, A patient with Moyamoya disease.
[0064] A flow diagram of the patient selection procedure is detailed in Figure 4 .
[0065] (method) Stroke disease subtypes were classified according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. We compared the presence or absence of the RNF213 p.R4810K polymorphism with atherosclerosis risk factors, family history of moyamoya disease, and characteristics of intracranial stenosis. Venous blood samples were used as DNA samples, which were anonymized and genotyped for p.R4810K using TaqMan SNP Assays (Applied Biosystems, Foster City, CA) and the 7300 / 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA) at the Department of Environmental Health Sciences, Kyoto University Graduate School.
[0066] (Statistical analysis) Continuous variables were expressed as mean ± SD and compared using Student's t-test. Categorical variables were expressed as numbers and percentages and compared using chi-square test and two-tailed Fisher's exact test. Odds ratios (OR ratios) and 95% confidence intervals (95% CI) were calculated for each stroke subtype. Variables considered in the model were age (continuous), sex, hypertension, dyslipidemia, type 2 diabetes, and smoking habits. All analyses were performed using JMP version 11.2.0 software (SAS Institute Inc., Cary, NC). Probability values were two-sided, and p < 0.05 was considered significant.
[0067] (result) The association between the background of all 70 patients and the RNF213 p.R4810K polymorphism is shown in Table 5. In Table 5, categorical variables are shown as the number of patients (%). The characteristics of the 17 patients who were carriers of the RNF213 p.R4810K polymorphism are shown in Table 6.
[0068] [Table 5]
[0069] [Table 6]
[0070] The notations in Table 6 have the following meanings: Bil; bilateral Right; Lt; left UE; undetermined etiology LAA; large artery atherosclerosis
[0071] Figure 5 is a pie chart showing the prevalence of the RNF213 p.R4810K polymorphism. The left pie chart is for all 70 patients in this study, and the right pie chart is for the general population as previously reported.
[0072] FIG. 6 is a pie chart showing the difference in prevalence of the RNF213 p.R4810K polymorphism between the sexes in this study, with the left pie chart for men (N=44) and the right pie chart for women (N-26).
[0073] Figure 7 is a pie chart showing the difference in the prevalence of the RNF213 p.R4810K polymorphism depending on the presence or absence of M1 / A1 stenosis in this study. The left pie chart is for those with stenosis (N = 48), and the right pie chart is for those without stenosis (N = 22).
[0074] Figure 8 shows image data of a representative case with the RNF213 p.R4810K polymorphism in this study (Case 6 in Table 6). (A) is an MRI diffusion-weighted image, showing scattered high signal areas in the left middle cerebral artery region. (B) is an MRA image, showing moderate stenosis in the left M1 segment. (C) is an MRA image taken 5 years after the onset of cerebral infarction, showing progression of stenosis in the left M1 segment.
[0075] The RNF213 p.R4810K polymorphism was found in 17 (24%) patients, with a female predominance (38% female vs. 16% male, OR 3.3, 95% CI 1.1-10.2, p=0.045). Thirty-five percent of patients with proximal middle cerebral artery (M1) or proximal anterior cerebral artery (A1) stenosis had this polymorphism (OR 25.0, 95% CI 1.4-437.8, p<0.01). Fifty-six percent of patients with multiple M1 / A1 stenoses had this polymorphism (OR 5.1, 95% CI 1.2-21.9, p=0.033).
[0076] (Consideration) This study showed that the prevalence of the RNF213 p.R4810K polymorphism was high in patients with cerebral arterial stenosis of the anterior circulation, especially M1 or A1 stenosis. A high prevalence of the p.R4810K polymorphism was observed in young patients with a lower vascular risk compared to elderly patients, suggesting that the p.R4810K polymorphism may be associated with the onset of cerebral infarction. In addition, in this study, which included intracranial anterior and posterior circulation and distal stenosis, this gene polymorphism was frequently found in patients with M1 / A1 stenosis, and an association between this gene polymorphism and the location of intracranial stenosis was revealed.
[0077] (Conclusion) From the above, it can be seen that the RNF213 p.R4810K polymorphism is correlated with young-onset non-cardiogenic cerebral infarction patients accompanied by cerebral artery stenosis of the anterior circulation system, particularly M1 or A1 stenosis.
[0078] (References) 1) Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O’Donnell M, Venketasubramanian N, Barker-Collo S, Lawes CMMM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C, Global Burden of Diseases, Injuries and RFS 2010 (GBD 2010) and the GSEG. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014;383:245-254. 2) GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459-1544. 3) Bang OY. Considerations when subtyping ischemic stroke in Asian patients. J Clin Neurol. 2016;12:129-136. 4) Gulli G, Rutten-Jacobs LCA, Kalra L, Rudd AG, Wolfe CDA, Markus HS. Differences in the distribution of stroke subtypes in a UK black stroke population - final results from the South London Ethnicity and Stroke Study. BMC Med. 2016;14:77. 5) Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke. 2001;32:2735-2740. 6) Mehndiratta MM, Khan M, Mehndiratta P, Wasay M. Stroke in Asia: geographical variations and temporal trends. J Neurol Neurosurg Psychiatry. 2014;85:1308-1312. 7) Malik R, Chauhan G, Traylor M, Sargurupremraj M, Okada Y, Mishra A, Rutten-Jacobs L, Giese AK, van der Laan SW, Gretarsdottir S, Anderson CD, Chong M, Adams HHH, Ago T, Almgren P, Amouyel P, Ay H, Bartz TM, Benco TM, Beglivan, Bonco, SGB, Bonco RD, Butterworth AS, Carrera C, Carty CL, Chasman DI, Chen WM, Cole JW, Correa A, Cotlarciuc I, Cruchaga C, Danesh J, de Bakker PIW, DeStefano AL, den Hoed M, Duan Q, Engelter ST, Falcone GJ, Gottesman RF, Gustavson V, Gustavson SRP, Gustavson Haessler J, Harris TB, Hassan A, Havulinna AS, Heckbert SR, Holliday EG, Howard G, Hsu FC, Hyacinth HI, Ikram MA, Ingelsson E, Irvin MR, Jian X, Jimenez-Conde J, Johnson JA, Jukema JW, Kanai M, Keene KL, Kisse BM, CDO, Kooperberg, Kubodorberg M, Lange LA, Langefeld CD, Langenberg C, Launer LJ, Lee JM, Lemmens R, Leys D, Lewis CM, Lin WY, Lindgren AG, Lorentzen E, Magnusson PK, Maguire J, Manichaikul A, McArdle PF, Meschia JF, Mitchell BD, Mosley TH, Nall MA, O’Donom TJ, T’DonomPsaty BM, Pulit SL, Rannikmae K, Reiner AP, Rexrode KM, Rice K, Rich SS, Ridker PM, Rost NS, Rothwell PM, Rotter JI, Rundek T, Sacco RL, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet. 2018;50:524-537., 8) Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, Hashikata H, Matsuura N, Yamazaki S, Toyoda A, Kikuta K, Takagi Y, Harada KH, Fujiyama A, Herzig R, Krischek B, Zou L, Kim JE, Kitakaze M, Miyamoto S, Nagata K, Hashimoto N, Koizumi A. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One. 2011;6:e22542. 9) Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, Kanno J, Niihori T, Ono M, Ishii N, Owada Y, Fujimura M, Mashimo Y, Suzuki Y, Hata A, Tsuchiya S, Tominaga T, Matsubara Y, Kure S. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet. 2011;56:34-40. 10) Miyawaki S, Imai H, Takayanagi S, Mukasa A, Nakatomi H, Saito N. Identification of a genetic variant common to moyamoya disease and intracranial major artery stenosis / occlusion. Stroke. 2012;43:3371-3374. 11) Miyatake S, Miyake N, Touho H, Nishimura-Tadaki A, Kondo Y, Okada I, Tsurusaki Y, Doi H, Sakai H, Saitsu H, Shimojima K, Yamamoto T, Higurashi M, Kawahara N, Kawauchi H, Nagasaka K, Okamoto N, Mori T, Koyano S, Kuroiwa Y, Taguri M, Morita S, Matsubara Y, Kure S, Matsumoto N. Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology. 2012;78:803-810. 12) Morito D, Nishikawa K, Hoseki J, Kitamura A, Kotani Y, Kiso K, Kinjo M, Fujiyoshi Y, Nagata K. Moyamoya disease-associated protein mysterin / RNF213 is a novel AAA+ ATPase, which dynamically changes its oligomeric state. Sci Rep. 2014;4:4442. 13) Koizumi A, Kobayashi H, Hitomi T, Harada KH, Habu T, Youssefian S. A new horizon of moyamoya disease and associated health risks explored through RNF213. Environ Health Prev Med. 2016;21:55-70. 14) Morimoto T, Enmi J, Hattori Y, Iguchi S, Saito S, Harada KH, Okuda H, Mineharu Y, Takagi Y, Youssefian S, Iida H, Miyamoto S, Ihara M, Kobayashi H, Koizumi A. Dysregulation of RNF213 promotes cerebral hypoperfusion. Sci Rep. 2018;8:3607. 15) Bang OY, Chung J-W, Cha J, Lee MJ, Yeon JY, Ki C-S, Jeon P, Kim J-S, Hong SC. A Polymorphism in RNF213 Is a Susceptibility Gene for Intracranial Atherosclerosis. PLoS One. 2016;11:e0156607. 16) O’Donnell M, Xavier D, Diener C, Sacco R, Lisheng L, Zhang H, Pias P, Truelsen T, Chin SL, Rangarajan S, Devilliers L, Damasceno A, Mondo C, Lanas F, Avezum A, Diaz R, Varigos J, Hankey G, Teal P, Kapral M, Ryglewicz D, Czlonkowska A, Skowronska M, Lopez-Jaramillo P, Dans T, Langhorne P, Yusuf S, INTERSTROKE investigators. Rationale and design of INTERSTROKE: a global case-control study of risk factors for stroke. Neuroepidemiology. 2010;35:36-44. 17) Fukui M. Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis (“moyamoya” disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan. Clin Neurol Neurosurg. 1997;99 Suppl 2:S238-240. 18) Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35-41. 19) Chimowitz MI, Kokkinos J, Strong J, Brown MB, Levine SR, Silliman S, Pessin MS, Weichel E, Sila CA, Furlan AJ. The Warfarin-Aspirin Symptomatic Intracranial Disease Study. Neurology. 1995;45:1488-1493. 20) Kim BJ, Kim JS. Ischemic stroke subtype classification: an Asian viewpoint. J stroke. 2014;16:8-17. 21) Park MG, Shin JH, Lee SW, Park HR, Park KP. RNF213 rs112735431 polymorphism in intracranial artery steno-occlusive disease and moyamoya disease in Koreans. J Neurol Sci. 2017;375:331-334. 22) Miyawaki S, Imai H, Shimizu M, Yagi S, Ono H, Mukasa A, Nakatomi H, Shimizu T, Saito N. Genetic variant RNF213 c.14576G>A in various phenotypes of intracranial major artery stenosis / occlusion. Stroke. 2013;44:2894-2897. 23) Kuroda S, Houkin K. Moyamoya disease: current concepts and future perspectives. Lancet Neurol. 2008;7:1056-1066. 24) Kuriyama S, Kusaka Y, Fujimura M, Wakai K, Tamakoshi A, Hashimoto S, Tsuji I, Inaba Y, Yoshimoto T. Prevalence and clinicoepidemiological features of moyamoya disease in Japan: findings from a nationwide epidemiological survey. Stroke. 2008;39:42-47. 25) Roy-O’Reilly M, McCullough LD. Sex differences in stroke: the contribution of coagulation. Exp Neurol. 2014;259:16-27. 26) Williams JE, Chimowitz MI, Cotsonis GA, Lynn MJ, Waddy SP, WASID Investigators. Gender differences in outcomes among patients with symptomatic intracranial arterial stenosis. Stroke. 2007;38:2055-2062. 27) Liu W, Senevirathna STMLD, Hitomi T, Kobayashi H, Roder C, Herzig R, Kraemer M, Voormolen MHJ, Cahova P, Krischek B, Koizumi A. Genomewide association study identifies no major founder variant in Caucasian moyamoya disease. J Genet. 2013;92:605–609.
Claims
1. A detection step of detecting the presence or absence of RNF213 p.R4810K gene polymorphism in a sample derived from a subject who has not yet experienced cerebral infarction; A determination step of determining whether or not the subject has a high probability of developing cerebral infarction based on the presence or absence of the RNF213 p.R4810K polymorphism in the detection step and the gender information of the subject; Including, When the RNF213 p.R4810K polymorphism is detected in the detection step, the determination step determines that, if the subject is female, the female subject having the RNF213 p.R4810K polymorphism has a higher risk of developing atherothrombotic cerebral infarction due to intracranial anterior circulation artery stenosis than individuals (males and females) not having the RNF213 p.R4810K polymorphism.
2. A detection step of detecting the presence or absence of RNF213 p.R4810K gene polymorphism in a sample derived from a subject who has not yet experienced cerebral infarction; A determination step of determining whether or not the subject has a high probability of developing cerebral infarction based on the presence or absence of the RNF213 p.R4810K polymorphism in the detection step and the gender information of the subject; Including, When the RNF213 p.R4810K polymorphism is detected in the detection step, the determination step determines that, if the subject is female, the female subject having the RNF213 p.R4810K polymorphism has a higher risk of developing atherothrombotic cerebral infarction due to intracranial anterior circulation artery stenosis than a male subject having the RNF213 p.R4810K polymorphism.
Citation Information
Patent Citations
Method for detecting genetic risk of cerebrovascular disorder
JP2007215537A
Method for predicting severe moyamoya disease by using RNF213 genetic polymorphism
JP2013034451A
Gene associated with arteriosclerotic disease, and use thereof
WO2007123233A1
Method for predicting brain infarction onset risk
WO2020121489A1
